The Extended Salford Lung Study (Ex-SLS) Data Access Project

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The Salford Lung Study (SLS) subjects represent a group of COPD and asthma patients whose disease is extremely well-characterised over a short time period. Subjects in the SLS originally consented for information relevant to the study to be shared with the sponsor (GSK). These data were limited to three years prior to randomisation and the twelve-month interventional treatment period. Broadened access to patients' data would allow SLS subjects' entire disease journey to be researched, presenting a rare opportunity to improve scientific and clinical understanding of COPD/asthma disease risk, treatment and progression. This proposal seeks to collect additional subject-level data from SLS patients via their electronic medical records (encompassing past and future data for up to 10 years from the date of consent) and via a one-off patient questionnaire administered at the time of consent.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Subjects who were randomized to treatment in the original SLS studies

• Subjects who are able to, and choose to, provide written consent for the additional information to be collected.

Locations
Other Locations
United Kingdom
GSK Investigational Site
RECRUITING
Manchester
Contact Information
Primary
US GSK Clinical Trials Call Center
GSKClinicalSupportHD@gsk.com
877-379-3718
Backup
EU GSK Clinical Trials Call Center
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
Time Frame
Start Date: 2018-04-15
Estimated Completion Date: 2028-04-30
Participants
Target number of participants: 3500
Treatments
Chronic obstructive pulmonary disease
Subjects with COPD who were randomised to treatment in the original SLS
Asthma
Subjects with asthma who were randomised to treatment in the original SLS.
Sponsors
Leads: GlaxoSmithKline

This content was sourced from clinicaltrials.gov

Similar Clinical Trials